Hypofractionated re-irradiation + MANNITOL + Cetuximab for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Jun 2016: Trial registered, NCT02800486

The trials

NCT02800486: Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

State
Under way
Phase
Phase 2
People
37 planned
Started
May 2016
Primary completion
May 2035
Arms
Intra-arterial Cetuximab with Re-Irradiation
Results
None posted
  1. 15 Jun 2016: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.